A new method to identify and isolate cancer-fighting T cells.
A streamlined, high-throughput platform for validation of cancer antigen presentation and isolation of cancer antigen reactive T cells
This study is working on a new technology to help find and target cancer cells more quickly using your own immune cells, so patients can get faster and more personalized treatments for cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10696045 on NIH RePORTER |
What this research studies
This research focuses on developing a technology called AbTR that aims to quickly identify cancer antigens presented on tumor cells and isolate T cells that can effectively target these cancer cells. By addressing the challenges of slow detection and isolation of specific T cells, this project seeks to enhance the effectiveness of T cell receptor-based immunotherapies. Patients may benefit from faster and more personalized treatment options that harness their own immune cells to fight cancer. The approach involves advanced techniques to analyze tumor samples and rapidly produce T cell clones that are ready for therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who may benefit from T cell receptor-based immunotherapy.
Not a fit: Patients with cancers that do not express identifiable antigens or those who are not eligible for immunotherapy may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer immunotherapies for patients.
How similar studies have performed: Other research has shown promise in T cell receptor-based immunotherapies, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Jiang, Ning Jenny — University of Pennsylvania
- Study coordinator: Jiang, Ning Jenny
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.